Streamlining Conformity Assessment with FDA's ASCA Program

Eric Franca, Ph.D.

Director, Conformity Assessment Program

Assistant Director, Division of Standards and Conformity Assessment (DSCA)



Center for Devices and Radiological Health Division of Standards and Conformity Assessment





Topics

- The Accreditation Scheme for Conformity Assessment (ASCA)
- Benefits of participating in ASCA
- Real-world examples of ASCA testing
- Citing ASCA testing in device submissions
- Question and answer session

THE ACCREDITATION SCHEME FOR CONFORMITY ASSESSMENT (ASCA)



What is ASCA?

- Capitalizes on FDA-recognized voluntary consensus standards in device development and review
- 'Puts standards to work' in conformity assessment
- ASCA Accreditation from FDA to qualified test labs means:
 - Confidence in their methods and results
 - No need for complete test report review

ISO/IEC 17011:2017 Conformity assessment — Requirements for accreditation bodies accrediting conformity assessment bodies



← Popular standards ISO/IEC 17025 Testing and calibration laboratories



ASCA Standards: Biocompatibility

- Majority of medical devices need biocompatibility assessment
- ASCA includes the nine most common biocompatibility test methods
- Nine ASCA Summary Test Report templates are available

FDA Recognized Consensus Standard	Test Method(s)
ISO 10993-4	Complement Activation using a U.S. marketed ELISA kit
ISO 10993-4 and ASTM F756	Direct and Indirect Hemolysis
ISO 10993-5	MEM Elution Cytotoxicity
ISO 10993-23*	In Vivo Dermal Irritation, Intracutaneous Reactivity Irritation
ISO 10993-10*	Closed Patch Sensitization
ISO 10993-10* and ASTM F720	Guinea Pig Maximization Sensitization
ISO 10993-11	Acute Systemic Toxicity
ISO 10993-11 and USP 151	Material-Mediated Pyrogenicity
ISO 10993-12	Sample preparation for all test types

*ISO 10993-10:2010 split into ISO 10993-10:2021 and ISO 10993-23:2021. *ISO 10993-10:2010, ISO 10993-10:2021, and ISO 10993-23:2021 are all included in ASCA.



ASCA Standards: Basic Safety and Essential Performance

- 82 standards
- Broad utilization across all medical electrical devices
- One ASCA Summary Test Report template

Standard	Standard Title
IEC 60601-1	Medical electrical equipment – Part 1: General requirements for basic safety and essential performance (along with the FDA-recognized collateral and particular standards in the IEC/ISO 60601-80601 series)
IEC 61010-1	Safety requirements for electrical equipment for measurement, control, and laboratory use – Part 1: General requirements (along with the FDA-recognized particular standards in the IEC 61010 series)



BENEFITS OF PARTICIPATING IN ASCA

ASCA Goal: Streamline Conformity Assessment in Pre-market Review



Benefits of ASCA:

- Removes the guesswork about supporting documentation needs
- Provides templates for the only documentation needed:
 - ASCA Declaration of Conformity
 - ASCA Summary Test Report

ASCA Test Method: Cytotoxicity – MEM Elution (ISO 10993-5) Administrative Information 1. Testing Laboratory Name: Test Lab ABC 2. ASCA Testing Laboratory Identification Number: TL-999 3. Testing Location(s): 123 Main St, XXX, Virginia 4. Testing Date(s): February 1 st , 2022 – February 28, 2022 5. ASCA Accreditation Status on the Date(s) of Testing: ☑ Standard (and particular test method) was in testing laboratory's ☑ ASCA Accreditation was not suspended ASCA Test Article Prep SOP#: <u>SOP-SamplePrep-123-Rev2.0, SOP-Sam</u> ☑ Test Article was prepared per the above protocol (no deviations/amendm □ Test Article was prepared per the above protocol, with the following dev filtering, extract manipulation, pH adjustment):	Appendix A: Example ASCA Declaration of Conformity (DOC) for Basic Safety and Essential Performance Standards in the ASCA Pilot Note: This example is intended to illustrate elements of the Declaration of Conformity per FDA's guidance Appropriate Use of Voluntary Consensus Standards in Premarket
Description of deviations/amendments	Submissions for Medical Devices that the device manufacturer submits as part of their premarket submission.
Test Article: ≥ Entire final finished device □ Representative sample selection per SOP □ Other: ² /DESCRIBE]	Responsible Party Name of entity responsible for DOC:
Extraction Solvent:	All identifying information for the product/device including (e.g., product code(s), device marketing name(s), model number(s), etc.).
□ Other: ³ [DESCRIBE] Extraction Ratio: □ 3 cm ³ /ml (<0.5mm thick) □ 3 cm ³ /ml (0.5-1.0mm thick or molded items > 1.0mm) □ 1.25cm ³ /ml (elastomers > 1.0mm thick) □ Other: ⁴ [DESCRIBE] Extraction Conditions: □ 37°C, 24 h ⊠ 37°C, 72 h □ 50°C, 72 h	Statement of Conformity □ The test results demonstrate that the device is in conformity with the standard(s) listed below ¹³ : • Title of Standard: (e.g., ANSI/AAMI ES60601-1 Medical electrical equipment - Part 1: General requirements for basic safety and essential performance.) • FDA Recognition #: (e.g., 19-4) • Options Selected □ Standard included no options
☐ 70°C, 24 h ☐ 121°C, 1 h ☐ Other: ⁵ [<i>DESCRIBE</i>]	List of options selected in standard (e.g., clause 5.3 permits modified test conditions if ambient temperature cannot be maintained). No information is needed in this section if testing is from an ASCA-accredited test lab; instead, this section may reference the ASCA summary test report provided as supplementary documentation.
	 Supprementary documentation. Testing Laboratory ABC) ASCA Testing Laboratory Identification Number (as applicable): <u>(e.g., ASCA001)</u> Testing Location(s): <u>(e.g., 1234 Example Road, Silver Spring, MD 20993)</u> Testing Date(s): <u>(e.g., Sep 1, 2020 – Sep 15, 2020)</u> ASCA Accreditation Status on the Date(s) of Testing:

□ Standard was not in testing laboratory's scope of ASCA Accreditation □ Standard was in testing laboratory's scope of ASCA Accreditation;

ASCA Benefits, continued

- FDA
- Reduces time needed for the conformity assessment element of device review
- Less need for Additional Information questions, lengthy internal consults and complete test report review
- Improves the quality of testing and reporting
 - Addresses testing issues for which
 FDA commonly identifies concerns



IEC 60601-1-2 Review: ASCA vs. Non-ASCA

- IEC 60601-1-2: complete test reports include images of the test set-up
 - Poor or unclear test set-ups, could raise deficiencies (see example below):

In your electromagnetic compatibility (EMC) report, you stated that the testing is done on the x, y, and zaxes. However, in your test setup, you have shown the horizontal plane is improperly oriented and has a coil size smaller than the full equipment under test (EUT). This standard is intended to demonstrate common and reproducible basis for evaluating the performance of your device applications when subjected to magnetic fields at power frequency. The processing unit of the device should be exposed during testing. We request that you clarify how the EUT was exposed to x, y, and z axes given the demonstrated test setup. If the processing system was not adequately exposed, we request that you perform new testing demonstrating the device is safe when subjected to magnetic fields at power frequency.

- Using ASCA, we have confidence in ASCA-accredited labs' methods and results
 - No deficiencies would be identified for testing methodology/set-up

REAL-WORLD EXAMPLES OF ASCA TESTING



Real World Example: non-ASCA vs. ASCA Testing

Class II Device	Non-ASCA Testing (IEC 60601-1-2)	ASCA Testing (ANSI/AAMI ES60601-1)
Deficiencies	1 major 3 minor	0
Length of report	46 pages	9 pages

Real World Example: non-ASCA vs. ASCA Testing

Class II Device	Non-ASCA Testing (60601-1 + 60601-2-2)	ASCA Testing (60601-1 + 60601-2-2)
Deficiencies	1 major	0
Length of report	203 pages	4 pages



ASCA Wound Therapy Device Submission: Basic Safety and Essential Performance Assessment

- Negative Pressure Wound Therapy Powered Suction Pump
 - device that promotes wound healing by the removal of excess exudates, infectious material, and tissue debris
- Basic Safety and Essential Performance ASCA testing:
 - IEC 60601-1
 - IEC 60601-1-2
 - IEC 60601-1-6
 - IEC 60601-1-8
 - IEC 60601-1-11

ASCA Wound Therapy Device Submission: Basic Safety and Essential Performance Review

60601-1 and all collaterals	Complete Test Reports (provided alongside ASCA Summary Test Reports)	ASCA Testing: ASCA Summary Test Reports
Review staff		No need for consult
Page count	407 pages total	20 pages total
Estimate of review time	~ 10 hours	~ 1 hours
Deficiencies identified		0

ASCA Lancet Submission: Biocompatibility Assessment




Contact type


 Limited skin-contacting devices (<24 h)

ASCA Biocompatibility Assessment

- Intracutaneous Reactivity
 Irritation
- Guinea Pig Maximization Sensitization
- MEM Elution Cytotoxicity

ASCA Submission: Biocompatibility








Example ASCA Summary Test Report: Cytotoxicity


ASCA Test Method: Cytotoxicity – MEM Elution (ISO 10993-5) Administrative Information 1. Testing Laboratory Name: Test Lab ABC 2. ASCA Testing Laboratory Identification Number: TL-999 3. Testing Location(s): 123 Main St, XXX, Virginia 4. Testing Date(s): February 1 st , 2022—February 28, 2022 5. ASCA Accreditation Status on the Date(s) of Testing: ⊠ Standard (and particular test method) was in testing labor ⊠ ASCA Accreditation was not suspended ASCA Test Article Prep SOP#: <u>SOP-SamplePrep-123-Rev2.0, SG</u>		 The test article and extract I have particles. There were changes in colo was swelling/degradation of th ASCA Test Method SOP #: 2 Test was conducted per the Test was conducted per the deviations/amendments:6 	r/turbidity or e test article. SOP-ASCA-N above protoc	particles in the 5 <u>MEM-789-Rev2.</u> col (no deviation	test article and/or ext 0 ns/amendments) and 2	ract OR there
Itest Article was prepared per the above protocol (no deviations/a)						
Test Article was prepared per the above protocol, with the follow			its			
filtering, extract manipulation, pH adjustment):						
Description of deviations/amendments	8 p a	iges	br ults	72 <u>hr</u> Results	Conclusion	
Fest Article:						_
Entire final finished device		•	ide	Grade 0/0/0	Performed as	
Representative sample selection per SOP		ninitac)/0		expected	_
Other:2 [DESCRIBE]	20-40 n	IIIIULES	ade)/0	Grade 0/0/0	Performed as	
			ade	Grade 4/4/4	expected Performed as	-
Extraction Solvent:			1/4	Grade 4/4/4	expected	
MEM with 5-10% animal serum		1 est Article Extract (100%	Grade	Grade 0/0/0	Non-cytotoxic	-
Other: ³ [DESCRIBE] Extraction Ratio:		neat)	0/0/0			
⊠ 6cm ² /ml (<0.5mm thick)						
\square 3 cm ² /ml (0.5-1.0mm thick or molded items > 1.0mm)		I confirm that:				
\square 1.25cm ² /ml (elastomers > 1.0mm thick)		Main The above summary inform	ation include	es all original ar	d any retest data; and	
□ Other:4 [DESCRIBE]		I have checked that there are	e no differen	ces between the	complete test report a	and this ASCA
Extraction Conditions:		summary test report.				
□ 37°C, 24 h						
⊠ 37°C, 72 h						
□ 50°C, 72 h		John Standards			3/1	15/2022
□ 70°C, 24 h		Name: [TYPED NAME POSI	TION]			Date
$\square 121^{\circ}C, 1h$						
□ Other: ⁵ [DESCRIBE]						

ASCA Submission: Biocompatibility



ASCA Submission: Biocompatibility





	Biocompatibility Justification at Day 0	Using ASCA Testing from Day 0
Deficiencies	1 major	0
FDA Days	76	~49 (or less)
Total Days after Day 0	189	~49 (or less)



CITING ASCA TESTING IN DEVICE SUBMISSIONS

ASCA Submission Elements

Cover Letter	 States that submission has ASCA testing Name, location and IDs of test lab(s) FDA-recognized consensus standard(s) and test methods used
ASCA Declaration of Conformity (DOC)	 Manufacturer provides the DOC ASCA Accreditation status for the test lab Please use example DOCs in ASCA guidances
ASCA Summary Test Report	• See standards-specific ASCA guidance documents for examples

Contains Nonbinding Recommendations

Electronic Submission Template for Medical Device 510(k) Submissions

Guidance for Industry and Food and Drug Administration Staff

Document issued on September 22, 2022.

The draft of this document was issued on September 29, 2021.

For questions about this document regarding CDRH-regulated devices, contact ORP: Office of Regulatory Programs at 301-796-5640 or <u>eSubPilot@fda.hhs.gov</u>. For questions about this document regarding CBER-regulated devices, contact the Office of Communication, Outreach, and Development (OCOD) at 1-800-835-4709 or 240-402-8010, or by email at <u>ocod@fda.hhs.gov</u>.



U.S. Department of Health and Human Services Food and Drug Administration Center for Devices and Radiological Health Center for Biologics Evaluation and Research

What is eSTAR?

- A dynamic PDF submission template for medical device submissions
- Features automation, guides, integrated databases, policies and procedures
- Guides applicant step by step through the device submission process

Two templates

- nIVD and IVD
- Available at: https://www.fda.gov/medicaldevices/premarket-notification-510k/voluntaryestar-program

FD



Documenting Standards in eSTAR

	Standard	ls	?
Add Standard	used, or there were deviations, cite the	ubmission (if any). If only certain sections were se in an attachment. A recognition number is e help text. Instead of typing in information, rmation be attached.	•
ISO -	10993-10 Fourth edition 2021-11	2-296 Delete Standar	rd
Biological evaluat	ion of medical devices - Part 10: Tests for sk	in sensitization	
Are you using this declaring conform	s standard for general use, or are you nity to it?	Declaration of Conformity with ASCA	?
	Add Standa	rd	
		General Use Declaration of Conformity Declaration of Conformity with A	ASC/



Documenting Standards in eSTAR: DOC


		Declaration of Conform	nity	
Application # 1200				
Company Name	Diamono	d Device Company		
Company Address	10 Main	Street Technopolis VA 99999 United Street Technopolis	States	
Device Trade Name	Gemstor	ne Device		
The subject device	(s) is in o	conformity with the requirements	of the followi	ng documents
Organization De	esignation	Number and Edition/Date		Recognition #
ISO 1	0993-10 F	Fourth edition 2021-11		2-296
Additional Information	(e.g., limit	ations on the validity of the Declaration	n of Conformity)	
Additional Information	(e.g., limit	ations on the validity of the Declaration	n of Conformity)	
Additional Information	(e.g., limit	ations on the validity of the Declaration	n of Conformity)	
		ations on the validity of the Declaration	n of Conformity)	
Signed for and on I	behalf of		n of Conformity) February 1, 20	24
	behalf of Date:	the applicant company:		24

Documenting ASCA Standards in eSTAR - Attachments



EMC, Wireless, Electrical, Mechanical, and Thermal Safety

Based on the answers provided in the Device Description section, EMC and wireless technology information is needed



** Attach the ASCA Summary Test Reports to the relevant eSTAR sections **

Biocompatibility


ased on the answer provided in the Device Description section, biocompatibility information is needed

Tissue Contacting Products/Components/Materials

How many tissue contacting products/components/materials are there? (See Help Text if multiple materials share the same justification for no testing.)

Biocompatibility Reports and Documentation

Please attach any documentation (e.g., test reports) pertaining to the biocompatibility of your device. If no test reports were attached, please attach a rationale explaining Add Attachment why testing is not necessary.





Future

- ASCA is a permanent Program
- Draft Guidances out for comment
 - Link to Docket
- ASCA Expansion workshop held on April 17, 2024
 - Link to Workshop



Future

- ASCA Workshop on
 Potential Inclusion of
 Chemical Characterization
 Biocompatibility Method
 - November 6, 2024
 - Register here



FDA Industry Updates and Education

1. CDRH New

• Sign up at: https://public.govdelivery.com/accounts/USFDA/subscribers/qualify

2. CDRH Learn: Multi-Media Industry Education

- Videos, audio recordings, power point presentations, software-based "how to" modules
- <u>www.fda.gov/CDRHLearn</u>

3. Device Advice: Text-Based Education

- Comprehensive regulatory information on premarket and postmarket topics
- <u>www.fda.gov/DeviceAdvice</u>

4. Division of Industry and Consumer Education (DICE)

- Email: <u>DICE@fda.hhs.gov</u>
- Phone: 1(800) 638-2041 or (301) 796-7100 (Hours: 9 am-12:30 pm; 1 pm-4:30pm EST)
- Web: <u>www.fda.gov/DICE</u>

5. eSTAR Program

- <u>https://www.fda.gov/medical-devices/how-study-and-market-your-device/voluntary-estar-program?utm_medium=email&utm_source=govdelivery</u>
- eSTAR Assistance: <u>510K Program@fda.hhs.gov</u>
- Tech Questions/Feedback: <u>eSubpilot@fda.hhs.gov</u>



FDA Standards Resources

- Division of Standards and Conformity Assessment (DSCA) <u>www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/standards-</u> and-conformity-assessment-program#intro
- FDA Recognized Consensus Standards Database
 www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfStandards/search.cfm
- Non-recognized Standards Database
 https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfStandards/nr_results.cfm
- Email us at: <u>CDRHStandardsStaff@fda.hhs.gov</u>



Relevant FDA Guidances

- Recognition and Withdrawal of Voluntary Consensus Standards guidance www.fda.gov/regulatory-information/search-fda-guidance-documents/recognition-and-withdrawalvoluntary-consensus-standards
- Appropriate Use of Voluntary Consensus Standards in Premarket Submissions for Medical Devices guidance <u>www.fda.gov/regulatory-information/search-fda-guidance-documents/appropriate-use-voluntary-</u> <u>consensus-standards-premarket-submissions-medical-devices</u>
- Recommended Content and Format of Non-Clinical Bench Performance Testing Information in Premarket Submissions: Guidance for Industry and Food and Drug Administration Staff https://www.fda.gov/media/113230/download

ASCA Resources



www.fda.gov/medical-devices/standards-and-conformity-assessment-program/accreditationscheme-conformity-assessment-asca

• ASCA program guidance

https://www.fda.gov/regulatory-information/search-fda-guidance-documents/accreditationscheme-conformity-assessment-asca-pilot-program

- ASCA Standards-specific guidances
 - Basic Safety and Essential Performance standards-specific guidance: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/basic-safety-and-essential-performance-medical-electrical-equipment-medical-electrical-systems-and
 - Biocompatibility standards-specific guidance: <u>https://www.fda.gov/regulatory-information/search-fda-guidance-documents/biocompatibility-testing-</u> <u>medical-devices-standards-specific-information-accreditation-scheme</u>
- Ask ASCA! <u>ASCA@FDA.HHS.GOV</u>

FD)

ASCA Draft Guidances

- Draft ASCA Program Guidance: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/accreditation-scheme-conformity-assessment-asca-program
- Draft ASCA Biocompatibility Guidance: <u>https://www.fda.gov/regulatory-information/search-fda-guidance-documents/biocompatibility-</u> <u>testing-medical-devices-standards-specific-information-accreditation-scheme-0</u>
- Draft ASCA Basic Safety and EP Guidance: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/basic-safety-and-essential-performance-medical-electrical-equipment-medical-electrical-systems-and-0
- Docket for Commenting: <u>https://www.regulations.gov/docket/FDA-2019-D-3805/document</u>

FD

QUESTIONS

